1-9 of 9
Hiroyuki Shimada
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study

Available to Purchase
Suzanne Shusterman, Arlene Naranjo, Collin Van Ryn, Jaquelyn A. Hank, Marguerite T. Parisi, Barry L. Shulkin, Sabah Servaes, Wendy B. London, Hiroyuki Shimada, Jacek Gan, Steven D. Gillies, John M. Maris, Julie R. Park, Paul M. Sondel
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (20): 6044–6051.
https://doi.org/10.1158/1078-0432.CCR-19-0798
Published: 15 October 2019
View articletitled, Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study
Open the PDF for Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study in another window
Journal Articles

Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells

Available to Purchase
Hong-Wei Wu, Michael A. Sheard, Jemily Malvar, G. Esteban Fernandez, Yves A. DeClerck, Laurence Blavier, Hiroyuki Shimada, Charles P. Theuer, Richard Sposto, Robert C. Seeger
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (15): 4761–4774.
https://doi.org/10.1158/1078-0432.CCR-18-3358
Published: 01 August 2019
View articletitled, Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells
Open the PDF for Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells in another window
Includes: Supplementary data
Journal Articles

Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

Available to Purchase
Steven G. DuBois, Yael P. Mosse, Elizabeth Fox, Rachel A. Kudgus, Joel M. Reid, Renee McGovern, Susan Groshen, Rochelle Bagatell, John M. Maris, Clare J. Twist, Kelly Goldsmith, M. Meaghan Granger, Brian Weiss, Julie R. Park, Margaret E. Macy, Susan L. Cohn, Greg Yanik, Lars M. Wagner, Randall Hawkins, Jesse Courtier, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Najee Boucher, Scarlett Czarnecki, Chunqiao Luo, Denice Tsao-Wei, Katherine K. Matthay, Araz Marachelian
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (24): 6142–6149.
https://doi.org/10.1158/1078-0432.CCR-18-1381
Published: 13 December 2018
View articletitled, Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
Open the PDF for Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma in another window
Includes: Supplementary data
Journal Articles

Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis

Available to Purchase
Araz Marachelian, Judith G. Villablanca, Cathy W. Liu, Betty Liu, Fariba Goodarzian, Hollie A. Lai, Hiroyuki Shimada, Hung C. Tran, Jaime A. Parra, Richard Gallego, Nora Bedrossian, Sabrina Young, Scarlett Czarnecki, Rebekah Kennedy, Brian D. Weiss, Kelly Goldsmith, Meaghan Granger, Katherine K. Matthay, Susan Groshen, Shahab Asgharzadeh, Richard Sposto, Robert C. Seeger
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (18): 5374–5383.
https://doi.org/10.1158/1078-0432.CCR-16-2647
Published: 14 September 2017
View articletitled, Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis
Open the PDF for Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma

Available to Purchase
Steven G. DuBois, Susan Groshen, Julie R. Park, Daphne A. Haas-Kogan, Xiaodong Yang, Ethan Geier, Eugene Chen, Kathy Giacomini, Brian Weiss, Susan L. Cohn, M. Meaghan Granger, Gregory A. Yanik, Randall Hawkins, Jesse Courtier, Hollie Jackson, Fariba Goodarzian, Hiroyuki Shimada, Scarlett Czarnecki, Denice Tsao-Wei, Judith G. Villablanca, Araz Marachelian, Katherine K. Matthay
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (12): 2715–2721.
https://doi.org/10.1158/1078-0432.CCR-14-3240
Published: 14 June 2015
View articletitled, Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma
Open the PDF for Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma in another window
Includes: Supplementary data
Journal Articles

Prognostic significance of genomic alterations of metastatic neuroblastomas.

Free
Shahab Asgharzadeh, Roger Pique-Regi, Yuexian Tu, Richard Sposto, Hiroyuki Shimada, Antonio Ortega, Robert Seeger
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19_Supplement): A36.
Published: 15 August 2014
View articletitled, Prognostic significance of genomic alterations of metastatic neuroblastomas.
Journal Articles

Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial

Available to Purchase
Steven G. DuBois, Louis Chesler, Susan Groshen, Randall Hawkins, Fariba Goodarzian, Hiroyuki Shimada, Greg Yanik, Michael Tagen, Clinton Stewart, Yael P. Mosse, John M. Maris, Denice Tsao-Wei, Araz Marachelian, Judith G. Villablanca, Katherine K. Matthay
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (9): 2679–2686.
https://doi.org/10.1158/1078-0432.CCR-11-3201
Published: 30 April 2012
View articletitled, Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
Open the PDF for Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial in another window
Includes: Supplementary data
Journal Articles

Ewing Tumors That Do Not Overexpress BMI-1 Are a Distinct Molecular Subclass with Variant Biology: A Report from the Children's Oncology Group

Available to Purchase
Aaron Cooper, John van Doorninck, Lingyun Ji, Darren Russell, Marc Ladanyi, Hiroyuki Shimada, Mark Krailo, Richard B. Womer, Jessie Hao-ru Hsu, Dafydd Thomas, Timothy J. Triche, Richard Sposto, Elizabeth R. Lawlor
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (1): 56–66.
https://doi.org/10.1158/1078-0432.CCR-10-1417
Published: 04 January 2011
View articletitled, Ewing Tumors That Do Not Overexpress BMI-1 Are a Distinct Molecular Subclass with Variant Biology: A Report from the Children's Oncology Group
Open the PDF for Ewing Tumors That Do Not Overexpress BMI-1 Are a Distinct Molecular Subclass with Variant Biology: A Report from the Children's Oncology Group in another window
Journal Articles

Does MYCN Amplification Manifested as Homogeneously Staining Regions at Diagnosis Predict a Worse Outcome in Children with Neuroblastoma? A Children's Oncology Group Study

Available to Purchase
Lisa A. Moreau, Patrick McGrady, Wendy B. London, Hiroyuki Shimada, Susan L. Cohn, John M. Maris, Lisa Diller, A. Thomas Look, Rani E. George
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19): 5693–5697.
https://doi.org/10.1158/1078-0432.CCR-06-1500
Published: 04 October 2006
View articletitled, Does MYCN Amplification Manifested as Homogeneously Staining Regions at Diagnosis Predict a Worse Outcome in Children with Neuroblastoma? A Children's Oncology Group Study
Open the PDF for Does MYCN Amplification Manifested as Homogeneously Staining Regions at Diagnosis Predict a Worse Outcome in Children with Neuroblastoma? A Children's Oncology Group Study in another window